

10/099,836

(FILE 'HOME' ENTERED AT 15:33:52 ON 18 OCT 2004)

FILE 'STNGUIDE' ENTERED AT 15:33:58 ON 18 OCT 2004

FILE 'REGISTRY' ENTERED AT 15:36:49 ON 18 OCT 2004

L1 9 S PVLDFRELLNELLEALKQK/LSQEP

FILE 'CAPLUS' ENTERED AT 15:38:53 ON 18 OCT 2004

L2 5 S L1

L3 5 DUP REM L2 (0 DUPLICATES REMOVED)

FILE 'REGISTRY' ENTERED AT 15:39:44 ON 18 OCT 2004

L4 0 S PVLDFRELLNELLEALKQK/LSQFP

L5 19 S PVLDFRELLNELLEALKQK/LSQSFP

L6 19 S L5 AND 22-29/SQL

L7 10 S L6 NOT L1

FILE 'CAPLUS' ENTERED AT 15:40:45 ON 18 OCT 2004

L8 4 S L7

FILE 'REGISTRY' ENTERED AT 15:41:27 ON 18 OCT 2004

L9 62 S [AGQNDP] [AVIL] [LF] [ED] [LF] [LF] [TSHENQDKR] [EDHRK] [GL] [LWG] [TSH

L10 62 S L9 AND 22-29/SQL

L11 53 S L10 NOT L1

L12 43 S L11 NOT L7

FILE 'CAPLUS' ENTERED AT 15:44:33 ON 18 OCT 2004

L13 4 S L12

L14 36 S (DASSEUX, J? OR DASSEUX J?)/AU,IN

L15 13 S (SEKUL, R? OR SEKUL R?)/AU,IN

L16 29 S (BUTTNER, K? OR BUTTNER K?)/AU,IN

L17 15 S (CORNUT, I? OR CORNUT I?)/AU,IN

L18 159 S (METZ, G? OR METZ G?)/AU,IN

L19 0 S (DUFOURCH, J? OR DUFOURCH J?)/AU,IN

L20 221 S L14 OR L15 OR L16 OR L17 OR L18 OR L19

L21 17 S L20 AND (APO?)

L22 17 DUP REM L21 (0 DUPLICATES REMOVED)

L23 17 S L22

L24 5 S L3

L25 12 S L22 NOT (L3 OR L8 OR L13)

L26 0 S L25 AND (D) (2A) (AMINO) (2A) (ACID?)

L27 0 S L25 AND (D-AMINO?)

L28 1861 S (APOA-I)

L29 5 S L28 AND (D) (2A) (AMINO) (2A) (ACID?)

L30 5 DUP REM L29 (0 DUPLICATES REMOVED)

L31 0 S L28 AND ENANTIOMER?

L32 4 S L28 AND D-AMINO?

L33 49 S (AMPHIPHATHIC) AND (D-AMINO)

L34 4 S L33 AND (STABL? OR STABILIZ?)

L35 61 S (AMPHIPHATHIC?) AND (D) (2A) (AMINO) (2A) (ACID?)

L36 61 DUP REM L35 (0 DUPLICATES REMOVED)

L37 61 S L36

L38 2 S L36 AND PHARM?

L39 61 S L33 OR L35

L40 4 S L39 AND CHOLES?

L41 55525 S (ORAL) (3A) (ADMINISTR?)

L42 27 S L41 AND (D) (2A) (AMINO) (3A) (ACID?)

L43 27 DUP REM L42 (0 DUPLICATES REMOVED)

L44 8 S BIOAVAILAB? (10A) (D) (2A) (AMINO) (3A) (ACID?)

L45 8 DUP REM L44 (0 DUPLICATES REMOVED)

=>

L1 ANSWER 1 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 618094-53-4 REGISTRY

SEQ 1 PVLDLFRELL NELLEALKQK LK

=====

HITS AT: 1-22

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

L1 ANSWER 2 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 503625-74-9 REGISTRY

SEQ 1 PVLDLFRELL NELLEALKQK LK

=====

HITS AT: 1-22

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

L1 ANSWER 3 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 222405-87-0 REGISTRY

SEQ 1 PVLDLFRELL NELLEALKQK LK

=====

HITS AT: 1-22

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

L1 ANSWER 4 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 221883-68-7 REGISTRY

SEQ 1 PVLDLFRELL NELLEALKQK LK

=====

HITS AT: 1-22

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

L1 ANSWER 5 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 221882-76-4 REGISTRY

SEQ 1 PVLDLFRELL NELLEALKQK LK

=====

HITS AT: 1-22

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

L1 ANSWER 6 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 221882-53-7 REGISTRY

SEQ 1 PVLDLFRELL NELLEALKQK LK

=====

HITS AT: 1-22

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

L1 ANSWER 7 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 221882-42-4 REGISTRY

SEQ 1 PVLDLFRELL NELLEALKQK LK

=====

HITS AT: 1-22

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

L1 ANSWER 8 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 221882-20-8 REGISTRY

SEQ 1 PVLDLFRELL NELLEALKQK LK  
===== ==  
HITS AT: 1-22

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

L1 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 221882-15-1 REGISTRY

SEQ 1 PVLDLFRELL NELLEALKQK LK  
===== ==  
HITS AT: 1-22

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

=>

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2003:855644 CAPLUS  
 DN 139:358775  
 TI Peptide and peptide analog apolipoprotein A-I agonists and their use to  
 treat dyslipidemic disorders  
 IN Dasseux, Jean-louis; Sekul, Renate; Buttner, Klaus; Cornut, Isabelle;  
 Metz, Gunther; Dufourcq, Jean  
 PA Germany  
 SO U.S. Pat. Appl. Publ., 146 pp., Cont. of U.S. Ser. No. 453,834.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003203842	A1	20031030	US 2002-99836	20020315
	US 6753313	B1	20040622	US 1999-453834	19991201
PRAI	US 1999-453834	A1	19991201		
	US 1997-940095	A1	19970929		
OS	MARPAT 139:358775				

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2003:242031 CAPLUS  
 DN 138:281126  
 TI Peptide and peptide analog apolipoprotein A-I agonists, and their use to  
 treat dyslipidemic disorders  
 IN Dasseux, Jean-louis; Sekul, Renate; Buttner, Klaus; Cornut, Isabelle;  
 Metz, Gunther  
 PA Germany  
 SO U.S. Pat. Appl. Publ., 135 pp., Cont.-in-part of U.S. 465,718.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003060604	A1	20030327	US 2002-99574	20020315
PRAI	US 1999-465718	A1	19991217		
OS	MARPAT 138:281126				

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1999:244556 CAPLUS  
 DN 130:301685  
 TI Peptide/lipid complex formation by co-lyophilization  
 IN Dasseux, Jean-Louis  
 PA USA  
 SO PCT Int. Appl., 42 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9917740	A1	19990415	WO 1998-US20330	19980928
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6287590	B1	20010911	US 1997-942597	19971002

CA 2305704	AA	19990415	CA 1998-2305704	19980928
AU 9896715	A1	19990427	AU 1998-96715	19980928
AU 749344	B2	20020627		
EP 1019025	A1	20000719	EP 1998-950743	19980928
EP 1019025	B1	20040303		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NZ 503721	A	20010831	NZ 1998-503721	19980928
JP 2001522781	T2	20011120	JP 2000-514617	19980928
EP 1358874	A1	20031105	EP 2003-15963	19980928
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
RU 2224506	C2	20040227	RU 2000-111523	19980928
AT 260644	E	20040315	AT 1998-950743	19980928
NO 2000001683	A	20000510	NO 2000-1683	20000331
US 6455088	B1	20020924	US 2000-642363	20000821
US 2003099714	A1	20030529	US 2002-252940	20020923
PRAI US 1997-942597	A	19971002		
EP 1998-950743	A3	19980928		
WO 1998-US20330	W	19980928		
US 2000-642363	A1	20000821		
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD				
ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1999:233813 CAPLUS  
 DN 130:276755  
 TI Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders  
 IN Dasseux, Jean-Louis; Sekul, Renate; Buttner, Klaus; Cornut, Isabelle; Metz, Gunther; Dufourcq, Jean  
 PA USA  
 SO PCT Int. Appl., 280 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9916459	A1	19990408	WO 1998-US20327	19980928
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6004925	A	19991221	US 1997-940095	19970929
	CA 2304805	AA	19990408	CA 1998-2304805	19980928
	AU 9897790	A1	19990423	AU 1998-97790	19980928
	AU 746090	B2	20020418		
	EP 1019073	A1	20000719	EP 1998-951978	19980928
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001518282	T2	20011016	JP 2000-513593	19980928
	NZ 503717	A	20020828	NZ 1998-503717	19980928
	RU 2215747	C2	20031110	RU 2000-111537	19980928
	US 6329341	B1	20011211	US 1999-453605	19991201
	US 6376464	B1	20020423	US 1999-453838	19991201
	US 6573239	B1	20030603	US 1999-453841	19991201
	US 6602854	B1	20030805	US 1999-453833	19991201
	US 6630450	B1	20031007	US 1999-453826	19991201
	US 6716816	B1	20040406	US 1999-453840	19991201
	NO 2000001599	A	20000502	NO 2000-1599	20000328

US 2004181034	A1	20040916	US 2004-802080	20040315
PRAI US 1997-940095	A	19970929		
WO 1998-US20327	W	19980928		
US 1999-453840	A1	19991201		

OS MARPAT 130:276755

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:233772 CAPLUS

DN 130:262129

TI Apolipoprotein A-I  $\alpha$ -helical peptide analogs as agonists for treatment of dyslipidemias

IN Dasseux, Jean-Louis; Sekul, Renate; Buttner, Klaus; Cornut, Isabelle; Metz, Gunther; Dufourcq, Jean

PA USA

SO PCT Int. Appl., 232 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9916409	A2	19990408	WO 1998-US20329	19980928	
	W:			AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:			GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	US 6518412	B1	20030211	US 1997-940136	19970929	
	CA 2304814	AA	19990408	CA 1998-2304814	19980928	
	EP 1039934	A1	20001004	EP 1998-950742	19980928	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI		
	NZ 503720	A	20021025	NZ 1998-503720	19980928	
	AU 758307	B2	20030320	AU 1998-96714	19980928	
	JP 2003525565	T2	20030902	JP 2000-513549	19980928	
	RU 2222545	C2	20040127	RU 2000-111526	19980928	
	NO 2000001601	A	20000526	NO 2000-1601	20000328	
	US 2003208059	A1	20031106	US 2002-283599	20021029	
PRAI	US 1997-940136	A	19970929			
	WO 1998-US20329	W	19980928			
OS	MARPAT 130:262129					

=>

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2003:855644 CAPLUS  
 DN 139:358775  
 TI Peptide and peptide analog apolipoprotein A-I agonists and their use to  
 treat dyslipidemic disorders  
 IN Dasseux, Jean-louis; Sekul, Renate; Buttner, Klaus; Cornut, Isabelle;  
 Metz, Gunther; Dufourcq, Jean  
 PA Germany  
 SO U.S. Pat. Appl. Publ., 146 pp., Cont. of U.S. Ser. No. 453,834.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003203842	A1	20031030	US 2002-99836	20020315
	US 6753313	B1	20040622	US 1999-453834	19991201
PRAI	US 1999-453834	A1	19991201		
	US 1997-940095	A1	19970929		
OS	MARPAT 139:358775				

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2003:242031 CAPLUS  
 DN 138:281126  
 TI Peptide and peptide analog apolipoprotein A-I agonists, and their use to  
 treat dyslipidemic disorders  
 IN Dasseux, Jean-louis; Sekul, Renate; Buttner, Klaus; Cornut, Isabelle;  
 Metz, Gunther  
 PA Germany  
 SO U.S. Pat. Appl. Publ., 135 pp., Cont.-in-part of U.S. 465,718.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003060604	A1	20030327	US 2002-99574	20020315
PRAI	US 1999-465718	A1	19991217		
OS	MARPAT 138:281126				

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1999:233813 CAPLUS  
 DN 130:276755  
 TI Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders  
 IN Dasseux, Jean-Louis; Sekul, Renate; Buttner, Klaus; Cornut, Isabelle;  
 Metz, Gunther; Dufourcq, Jean  
 PA USA  
 SO PCT Int. Appl., 280 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9916459	A1	19990408	WO 1998-US20327	19980928
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,				
	KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,				
	NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,				
	UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				
	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				
	CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

US 6004925	A	19991221	US 1997-940095	19970929
CA 2304805	AA	19990408	CA 1998-2304805	19980928
AU 9897790	A1	19990423	AU 1998-97790	19980928
AU 746090	B2	20020418		
EP 1019073	A1	20000719	EP 1998-951978	19980928
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001518282	T2	20011016	JP 2000-513593	19980928
NZ 503717	A	20020828	NZ 1998-503717	19980928
RU 2215747	C2	20031110	RU 2000-111537	19980928
US 6329341	B1	20011211	US 1999-453605	19991201
US 6376464	B1	20020423	US 1999-453838	19991201
US 6573239	B1	20030603	US 1999-453841	19991201
US 6602854	B1	20030805	US 1999-453833	19991201
US 6630450	B1	20031007	US 1999-453826	19991201
US 6716816	B1	20040406	US 1999-453840	19991201
NO 2000001599	A	20000502	NO 2000-1599	20000328
US 2004181034	A1	20040916	US 2004-802080	20040315
PRAI US 1997-940095	A	19970929		
WO 1998-US20327	W	19980928		
US 1999-453840	A1	19991201		
OS MARPAT 130:276755				
RE.CNT 3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD			
	ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:233772 CAPLUS

DN 130:262129

TI Apolipoprotein A-I  $\alpha$ -helical peptide analogs as agonists for treatment of dyslipidemias

IN Dasseux, Jean-Louis; Sekul, Renate; Buttner, Klaus; Cornut, Isabelle; Metz, Gunther; Dufourcq, Jean

PA USA

SO PCT Int. Appl., 232 pp.  
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9916409	A2	19990408	WO 1998-US20329	19980928
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6518412	B1	20030211	US 1997-940136	19970929
	CA 2304814	AA	19990408	CA 1998-2304814	19980928
	EP 1039934	A1	20001004	EP 1998-950742	19980928
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	NZ 503720	A	20021025	NZ 1998-503720	19980928
	AU 758307	B2	20030320	AU 1998-96714	19980928
	JP 2003525565	T2	20030902	JP 2000-513549	19980928
	RU 2222545	C2	20040127	RU 2000-111526	19980928
	NO 2000001601	A	20000526	NO 2000-1601	20000328
	US 2003208059	A1	20031106	US 2002-283599	20021029
PRAI	US 1997-940136	A	19970929		
	WO 1998-US20329	W	19980928		
OS	MARPAT 130:262129				



L13 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:855644 CAPLUS

DN 139:358775

TI Peptide and peptide analog apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

IN Dasseux, Jean-louis; Sekul, Renate; Buttner, Klaus; Cornut, Isabelle; Metz, Gunther; Dufourcq, Jean

PA Germany

SO U.S. Pat. Appl. Publ., 146 pp., Cont. of U.S. Ser. No. 453,834.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003203842	A1	20031030	US 2002-99836	20020315
	US 6753313	B1	20040622	US 1999-453834	19991201
PRAI	US 1999-453834	A1	19991201		
	US 1997-940095	A1	19970929		
OS	MARPAT 139:358775				

L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:242031 CAPLUS

DN 138:281126

TI Peptide and peptide analog apolipoprotein A-I agonists, and their use to treat dyslipidemic disorders

IN Dasseux, Jean-louis; Sekul, Renate; Buttner, Klaus; Cornut, Isabelle; Metz, Gunther

PA Germany

SO U.S. Pat. Appl. Publ., 135 pp., Cont.-in-part of U.S. 465,718.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003060604	A1	20030327	US 2002-99574	20020315
PRAI	US 1999-465718	A1	19991217		
OS	MARPAT 138:281126				

L13 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:233813 CAPLUS

DN 130:276755

TI Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

IN Dasseux, Jean-Louis; Sekul, Renate; Buttner, Klaus; Cornut, Isabelle; Metz, Gunther; Dufourcq, Jean

PA USA

SO PCT Int. Appl., 280 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9916459	A1	19990408	WO 1998-US20327	19980928
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

US 6004925	A	19991221	US 1997-940095	19970929
CA 2304805	AA	19990408	CA 1998-2304805	19980928
AU 9897790	A1	19990423	AU 1998-97790	19980928
AU 746090	B2	20020418		
EP 1019073	A1	20000719	EP 1998-951978	19980928
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001518282	T2	20011016	JP 2000-513593	19980928
NZ 503717	A	20020828	NZ 1998-503717	19980928
RU 2215747	C2	20031110	RU 2000-111537	19980928
US 6329341	B1	20011211	US 1999-453605	19991201
US 6376464	B1	20020423	US 1999-453838	19991201
US 6573239	B1	20030603	US 1999-453841	19991201
US 6602854	B1	20030805	US 1999-453833	19991201
US 6630450	B1	20031007	US 1999-453826	19991201
US 6716816	B1	20040406	US 1999-453840	19991201
NO 2000001599	A	20000502	NO 2000-1599	20000328
US 2004181034	A1	20040916	US 2004-802080	20040315
PRAI US 1997-940095	A	19970929		
WO 1998-US20327	W	19980928		
US 1999-453840	A1	19991201		
OS MARPAT 130:276755				
RE.CNT 3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD.			
	ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L13 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:233772 CAPLUS

DN 130:262129

TI Apolipoprotein A-I  $\alpha$ -helical peptide analogs as agonists for treatment of dyslipidemias

IN Dasseux, Jean-Louis; Sekul, Renate; Buttner, Klaus; Cornut, Isabelle; Metz, Gunther; Dufourcq, Jean

PA USA

SO PCT Int. Appl., 232 pp.  
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9916409	A2	19990408	WO 1998-US20329	19980928
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6518412	B1	20030211	US 1997-940136	19970929
	CA 2304814	AA	19990408	CA 1998-2304814	19980928
	EP 1039934	A1	20001004	EP 1998-950742	19980928
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	NZ 503720	A	20021025	NZ 1998-503720	19980928
	AU 758307	B2	20030320	AU 1998-96714	19980928
	JP 2003525565	T2	20030902	JP 2000-513549	19980928
	RU 2222545	C2	20040127	RU 2000-111526	19980928
	NO 2000001601	A	20000526	NO 2000-1601	20000328
	US 2003208059	A1	20031106	US 2002-283599	20021029
PRAI	US 1997-940136	A	19970929		
	WO 1998-US20329	W	19980928		
OS	MARPAT 130:262129				

L40 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1992:631070 CAPLUS

DN 117:231070

TI Turnover of synthetic class A **amphipathic** peptide analogs of exchangeable apolipoproteins in rats. Correlation with physical properties

MICRO FILM

AU Garber, David W.; Venkatachalapathi, Y. V.; Gupta, Kiran B.; Ibdah, Jamal; Phillips, Michael C.; Hazelrig, Jane B.; Segrest, Jere P.; Anantharamaiah, G. M.

CS Dep. Med., Univ. Alabama, Birmingham, AL, 35294, USA

SO Arteriosclerosis and Thrombosis (1992), 12(8), 886-94  
CODEN: ARTTE5; ISSN: 1049-8834

DT Journal

LA English

=> d 4 ab

L40 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AB Peptide analogs of the class A **amphipathic** helixes from exchangeable apolipoproteins mimic apolipoprotein (apo) A-I in a number of ways, including the ability to activate the enzyme lecithin: **cholesterol** acyltransferase, to associate with HDL, and to form HDL-like particles in the presence of lipids. This study investigated the metabolic properties of several of these peptide analogs in the rat. Peptide analogs studied were L-18A (which mimics apolipoprotein **amphipathic** helical domains in its charge distribution), 37pA (a dimer of two 18A monomers separated by a proline), 18R (with reversed charge distribution compared with 18A), and D-18A (identical in amino acid sequence to 18A but synthesized from **D-amino acids**). Peptides were radiolabeled with 125I. In addition, metabolism of rat and human 125I-apo A-I and human 14C-apo A-I was studied; no significant differences in clearance of these preps. were seen. Clearance data were fitted to multiexponential equations to give half-times of clearance; biexponential equations consistently provided the best nonlinear least-squares curve fit. The order of relative lipid affinity determined in vitro was 37pA > apo A-I > D-18A = L-18A > 18R. Half-times of clearance were in the same approx. rank order: 37pA and apo A-I, 6.9 h; D-18A, 4.0 h; L-18A, 4.6 h; and 18R, 0.9 h. Rats injected with L-18A had five times more radioactivity in the urine than did rats injected with D-18A. All urine radioactivity was present as free 125I in rats injected with L-18A or apo A-I but was present as intact peptide (with no free 125I) in rats injected with D-18A. The majority of radioactivity in L- and D-18A-injected rats was associated with the thyroid gland (in the case of L-18A), the liver, and the kidney. In summary, the rates of clearance of **amphipathic** helical peptides from the plasma compartment in rats decrease as the affinities of the peptides for lipoprotein surfaces increase. Stereoconformation did not affect the rate of clearance of peptide analogs. Although a significant proportion of radioactivity in L- and D-18A-injected animals was associated with the kidney, excretion of intact peptides in the urine did not appear to be a major route of clearance.

=>

L43 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2002:150357 CAPLUS  
DN 137:195286  
TI **Oral administration** of an apo A-I mimetic peptide  
synthesized from **D-amino acids** dramatically  
reduces atherosclerosis in mice independent of plasma cholesterol  
AU Navab, Mohamad; Anantharamaiah, G. M.; Hama, Susan; Garber, David W.;  
Chaddha, Manjula; Hough, Greg; Lallone, Roger; Fogelman, Alan M.  
CS Department of Medicine, University California, Los Angeles, CA,  
90095-1679, USA  
SO Circulation (2002), 105(3), 290-292  
CODEN: CIRCAZ; ISSN: 0009-7322  
PB Lippincott Williams & Wilkins  
DT Journal  
LA English  
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT